Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-24
    E.g., 2018-06-24


51061 items
4:12 PM, Jun 18, 2018  |  BC Extra | Clinical News

Antibodies neutralize Catalyst's Factor IX variant, crater stock

Catalyst Biosciences Inc. (NASDAQ:CBIO) fell $16.14 (64%) to $9.11 Monday when it reported that two patients developed neutralizing antibodies to CB 2679d (ISU 304). The antibodies were observed after treatment in the sixth and latest...
3:46 PM, Jun 18, 2018  |  BC Extra | Clinical News

PTC spikes on interim pivotal data for oral SMA candidate

PTC Therapeutics Inc. (NASDAQ:PTCT) gained $10.33 (28%) to $47.88 after reporting updated interim data from part 1 of the pivotal Phase II/III FIREFISH trial showing that oral risdiplam (RG7916) improved motor development scores in infants...
3:20 PM, Jun 18, 2018  |  BC Extra | Financial News

Qiming leads series B for cancer play WindMIL

WindMIL Therapeutics Inc. (Baltimore, Md.) raised $32.5 million in an untranched series B round led by Qiming Venture Partners. Fellow new investors Medivate Partners, Camden Partners Nexus and the Kinneret Group participated alongside existing investors...
3:11 PM, Jun 18, 2018  |  BC Extra | Company News

Vertex gets reimbursement deal for Orkambi in Sweden

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said Monday it agreed to a long-term access agreement for cystic fibrosis drug Orkambi lumacaftor/ivacaftor with Swedish authorities. Beginning July 1, Orkambi will be reimbursed in Sweden at an undisclosed price...
3:08 PM, Jun 18, 2018  |  BC Extra | Financial News

Stealth to start Phase IIb of AMD candidate with $100M financing

Stealth BioTherapeutics Inc. (Newton, Mass.) raised $100 million Monday through two convertible note rounds led by Nan Fung Technology's Pivotal Beta. Also participating were funds associated with Atlantis Investment Management, BVCF Management, CMBC Capital Holdings,...
3:00 PM, Jun 18, 2018  |  BC Extra | Company News

Management tracks: Ionis, Albireo

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) hired Damien McDevitt as CBO. He was SVP of corporate development at Acadia Pharmaceuticals Inc. (NASDAQ:ACAD). Hepatic disease company Albireo Pharma Inc. (NASDAQ:ALBO) hired Jason Duncan as general counsel. He was general...
2:38 PM, Jun 18, 2018  |  BC Extra | Company News

Valeant slides on psoriasis delay

Ortho Dermatologics said it received a complete response letter from FDA to an NDA for Duobrii (IDP-118) to treat plaque psoriasis. Ortho parent Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) slid $3.32 (12%) to $23.54 on...
11:26 AM, Jun 18, 2018  |  BC Extra | Clinical News

Medivir delays remetinostat Phase III

Medivir AB (SSE:MVIR B) lost SEK4.60 (12%) to SEK34.05 on Monday after announcing it will delay to 2019 the start of a Phase III trial of remetinostat in early stage cutaneous T-cell lymphoma (CTCL). The...
9:06 AM, Jun 18, 2018  |  BC Extra | Clinical News

FDA lifts clinical hold on Solid's DMD gene therapy

Solid Biosciences Inc. (NASDAQ:SLDB) said FDA lifted a clinical hold on the Phase I/II IGNITE DMD trial of microdystrophin gene transfer therapy SGT-001 to treat Duchenne muscular dystrophy (DMD). Solid plans to resume enrollment under...
7:32 AM, Jun 18, 2018  |  BC Extra | Company News

Allogene names Schmidt CFO

Cell therapy company Allogene Therapeutics Inc. (South San Francisco, Calif.) hired Eric Schmidt as CFO. Schmidt will remain a senior adviser at Cowen, where he was managing director and senior research analyst. A 20-year veteran of...